Search | IOVS | ARVO Journals

View

Showing 1 – 8 of 8

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2021

Dual angiopoietin-2 and VEGF-A inhibition with faricimab in neovascular age-related macular degeneration: phase 3 TENAYA and LUCERNE trial design

Robyn H Guymer; Carlos Quezada Ruiz; Jeffrey R Willis; David Silverman; Jane Ives; Karen Basu; Balakumar Swaminathan; Aachal Kotecha; Heather Boston; Hugh Lin

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):429. doi:

ARVO Annual Meeting Abstract June 2021

Faricimab in Neovascular Age-Related Macular Degeneration: 1-Year Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials

Arshad M. Khanani; Jeffrey Heier; Carlos Quezada Ruiz; Hugh Lin; David Silverman; Christopher Brittain; Jane Ives; Balakumar Swaminathan; Karen Basu; Tien Y Wong

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):428. doi:

ARVO Annual Meeting Abstract June 2021

Design and rationale of the YOSEMITE and RHINE trials: two phase 3 studies of faricimab in patients with diabetic macular edema

Nicole Eter; Jeffrey R Willis; Carlos Quezada Ruiz; Francis Abreu; Hugh Lin; David Silverman; Jane Ives; Karen Basu; Zdenka Haskova; Kemal Asik

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1043. doi:

ARVO Annual Meeting Abstract June 2021

Efficacy, durability, and safety of faricimab in diabetic macular edema (DME): one-year results from the phase 3 YOSEMITE and RHINE trials

John A Wells; Charles Clifton Wykoff; Jeffrey R Willis; Zdenka Haskova; Hugh Lin; David Silverman; Anthony P Adamis; Jane Ives; Francis Abreu; Karen Basu; Ramin Tadayoni

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1037. doi:

ARVO Annual Meeting Abstract June 2020

Clinical Effects of Blocking Ang-2 and VEGF with Faricimab in the Phase 2 STAIRWAY Trial

Carl J Danzig; Hugh Lin; Pascal Guibord; David Silverman; Carlos Quezada Ruiz; Ivo Stoilov; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1160. doi:

ARVO Annual Meeting Abstract July 2019

Efficacy and safety of faricimab every 16 or 12 weeks for neovascular age-related macular degeneration: STAIRWAY phase 2 results

Carl Danzig; Carlos Quezada; Karen Basu; Susanna Grzeschik; Jayashree Sahni; David Silverman; Aaron Osborne

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1212. doi:

Special Issue October 2018

Maximum Reading Speed in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

PDF

Rohit Varma; Eric H. Souied; Adnan Tufail; Elizabeth Tschosik; Daniela Ferrara; Jiameng Zhang; David Silverman; Chantal Dolan; Neil M. Bressler
TAGS: age-related macular degeneration, atrophy, reading speed, reading (activity), eye
Invest. Ophthalmol. Vis. Sci.. 2018; 59(4):AMD195-AMD201. doi: https://doi.org/10.1167/iovs.18-24238

ARVO Annual Meeting Abstract September 2016

Reliability and Construct Validity of National Eye Institute Visual Function Questionnaire-25 in Geographic Atrophy

Sobha Sivaprasad; Rohit Varma; Neil M Bressler; David Silverman; Miriam Kimel; Elizabeth Tschosik; Chantal Dolan

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):1980. doi:

Advertisement